Special Issue

Antiphospholipid Syndrome: From Pathophysiology to Novel Therapeutic Approaches

Message from the Guest Editor

The antiphospholipid syndrome (APS) is an autoimmune systemic disease characterized by a hypercoagulable state secondary to the presence of antiphospholipid antibodies (aPL), a cluster of autoantibodies directed against plasma proteins that bound membranes phospholipids. In particular, the most frequently found types of aPL are lupus anticoagulant (LA), anticardiolipin antibodies (aCL, IgG and IgM), and anti-β2-glycoprotein I antibodies (anti-β2GPI, IgG, and IgM). APS is clinically associated with vascular thromboses (venous, arterial, or small vessel) and/or pregnancy complications (recurrent embryonic or foetal loss, premature birth). The Special Issue, "Antiphospholipid Syndrome: From Pathophysiology to Novel Therapeutic Approaches", will focus on the pathophysiological mechanisms, clinical manifestations, and therapeutic approaches of antiphospholipid syndrome.

Guest Editor

Prof. Dr. Matteo Di Minno

Department of Translational Medical Sciences, Federico II University, Naples, Italy

Deadline for manuscript submissions

closed (31 May 2021)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed

mdpi.com/si/49096

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).